SBF
AVTX icon

Sara-Bay Financial’s Avalo Therapeutics AVTX Stock Holding History

Sara-Bay Financial’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-17
Closed -$5.18M – 80
2021
Q2 		$5.18M Buy
+17
New +$142K 1.95% 14

Other funds holding AVTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sara-Bay Financial's AVTX Position: Q3 2021 in Review

Sara-Bay Financial sold out of Avalo Therapeutics (AVTX) in Q3 2021, closing a stake of 17 shares — an estimated $5.18M sold.

Sara-Bay Financial first reported a position in AVTX in Q2 2021 and held it in 1 quarter. The position peaked at $5.18M in Q2 2021. 71 funds tracked by Wall St. Rank hold AVTX as of Q3 2021.

  • Sara-Bay Financial reported no remaining Avalo Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Sara-Bay Financial sold 17 Avalo Therapeutics shares in Q3 2021, an estimated $5.18M.
  • Sara-Bay Financial first reported a position in Avalo Therapeutics in Q2 2021 and held it in 1 quarter.
  • Sara-Bay Financial's Avalo Therapeutics position peaked at $5.18M in Q2 2021.
  • 71 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2021.

Based on Sara-Bay Financial's 13F filing for Q3 2021, filed 8 Oct 2021.